Compare AbbVie Inc (ABBV) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Fubotv Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Fubotv Inc trades at $9.65 (market cap $290.02M). The key difference: AbbVie Inc is far larger — about 1551.3× Fubotv Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| ABBV | FUBO | |
|---|---|---|
Market Cap | $449.91B | $290.02M |
Sector | Health | Technology |
52-Week High | $261.07 | $54.72 |
52-Week Low | $184.85 | $8.09 |
Enterprise Value | $513.38B | $460.44M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
FUBO trades at $9.85, down 3.43% today, with a neutral technical signal. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025, representing a significant turnaround to profitability. Recent developments include streaming partnerships with NBCUniversal and the BIG3 basketball league, while analyst consensus remains positive with a $16.25 price target.
FUBO presents a compelling turnaround story with improving profitability metrics and strong analyst support, though negative cash flow and high debt levels pose execution risks. The stock offers substantial upside potential if the company can maintain its path to sustainable profitability through content partnerships and advertising growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
